After the encouraging results of a prospective phase II study customizing chemotherapy according to ERCC1 gene expression [Simon G et al. 2007], Cobo et al. recently published the results from a prospective phase III randomized trial [Cobo et al. 2007], customizing cisplatin administration based on quantitative ERCC1 mRNA expression in tumours from patients with metastatic disease. This evidence concerns the gene ERCC1 and neoplasm.